Mutations in the Fas antigen in patients with multiple myeloma

Blood

Volumn 90, Issue 11, 1997, Pages 4266-4270

  Landowski, Terry H ^b   Qu, Ning ^b   Buyuksal, Ibrahim ^b   Painter, Jeffrey S ^b   Dalton, William S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MULTIPLE MYELOMA; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0030715354     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.11.4266.4266_4266_4270     Document Type: Article

References (41)

1. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Samashima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233, 1991
2. Nagata S, Golstein P: The Fas death factor. Science 267:1449, 1995
3. Itoh N, Nagata S: A novel protein domain required for apoptosis: Mutational analysis of human Fas antigen. J Biol Chem 268:10932, 1993
4. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME: Cytotoxicity-dependent APO-1 (Fas/ CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14:5579, 1995
5. Lynch DH, Ramsdell F, Alderson MR: Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 16:569, 1995
6. Nagata S: Apoptosis by death factor. Cell 88:355, 1997
7. Nagata S, Suda T: Fas and Fas ligand: lpr and gld mutations. Immunol Today 16:39, 1995
8. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314, 1992
9. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, de Villarty JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347, 1995
10. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935, 1995
11. Bettinardi A, Brugnoni D, Quiros-Rolden E, Malagoli A, La Grutta S, Correra A, Notarangelo D: Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: A molecular and immunological analysis. Blood 89:902, 1997
12. Le Deist F, Emile J-F, Rieux-Laucat F, Benkerrou M, Roberts I, Brousse N, Fischer A: Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 348:719, 1996
13. Drappa J, Vaishnaw AK, Sullivan KE, Chu J-L, Elkon KB: Fas gene mutations in the Canale-Smith syndrome, an inherited lymphroliferative disorder associated with autoimmunity. N Engl J Med 335:1643, 1996
14. Barlogie B, Epstein J, Selvanayagam P, Alexanian R: Plasma cell myeloma - New biological insights and advances in therapy. Blood 73:865, 1989
15. Niesvizky R, Siegel D, Michaeli J: Biology and treatment of multiple myeloma. Blood Rev 7:24, 1993
16. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T: Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 3:757, 1995
17. Westendorf JJ, Lammert JM, Jelinek DF: Expression and function of Fas (Apo-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 12:3466, 1995
18. Landowski TH, Gleason-Guzman MC, Dalton WS: Selection for drug resistance results in resistance to Fas mediated apoptosis. Blood 89:1180, 1997
19. Fiucci G, Ruberti G: Detection of polymorphisms within the Fas cDNA gene sequence by GC-clamp denaturing gradient gel electrophoresis. Immunogen 39:437, 1995
20. Wells D, Kedes L: Structure of a human histone cDNA: Evidence that basally expressed histone genes have intervening sequences and encode polyadenylated mRNAs. Proc Natl Acad Sci USA 82:2834, 1985
21. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T: Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86:2766, 1989
22. Poduslo SE, Dean M, Kolch U, O'Brien SJ: Detecting high-resolution polymorphisms in human coding loci by combining PCR and single-strand conformation polymorphism (SSCP) analysis. Am J Hum Genet 49:106, 1991
23. Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW, Stone EM: The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions. Genomics 16:325, 1993
24. Abbaszadegan MR, Cress AE, Futscher BW, Bellamy WT, Dalton WS: Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers. Cancer Res 56:5435, 1996
25. Wu JK, Ye Z, Darras BT: Sensitivity of single-strand conformation polymorphism (SSCP) analysis in detecting p53 point mutations in tumors with mixed cell populations. Am J Hum Genet 52:1273, 1993
26. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759, 1995
27. Cascino I, Fiucci G, Papoff G, Ruberti G: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154:2706, 1995
28. Hughes DPM, Crispe IN: A naturally occurring soluble iso-form of murine Fas generated by alternative splicing. J Exp Med 182:1395, 1995
29. Epstein J: Myeloma phenotype: Clues to disease origin and manifestation. Hematol Oncol Clin North Am 6:249, 1992
30. Greipp PR: Prognosis in myeloma. Mayo Clin Proc 69:895, 1994
31. Ju S-T, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373:444, 1995
32. Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z: Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol 166:236, 1995
33. Dirks W, Schone S, Uphoff C, Quentmeier H, Pradella S, Drexler HG: Expression and function of CD95 (Fas/APO-1) in leukaemia-lymphoma toumor lines. Br J Haematol 96:584, 1997
34. Mandik L, Nguyen K-AT, Erikson J: Fas receptor expression on B-lineage cells. Eur J Immunol 25:3148, 1995
35. Wang J, Taniuchi I, Maekawa Y, Howard M, Cooper MD, Watanabe T: Expression and function of Fas antigen on activated murine B cells. Eur J Immunol 26:92, 1996
36. Dianzani U, Bragardo M, DiFranco D, Alliaudi C, Scagni P, Buonfiglio D, Redoglia V, Bonissoni S, Correra A, Dianzani I, Ramenghi U: Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmunity/lymphoproliferation. Blood 89:2871, 1997
37. Dubrez L, Savoy I, Hamman A, Solary E: Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. EMBO J 15:5504, 1996
38. Datta R, Banach C, Kojima H, Talanian RV, Alnemri ES, Wong WW, Kufe DW: Activation of the CPP32 protease in apoptosis induced by 1-B-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood 88:1936, 1996
39. Friesen C, Herr I, Krammer PH, Debatin K-M: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 2:574, 1996
40. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 80:879, 1992
41. Robertson MJ, Manley TJ, Pichert G, Cameron C, Cochran KJ, Levine H, Ritz J: Functional consequences of Apo-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymph 17:51, 1995